This commentary focuses on the cytopathology laboratory, the authors' experiences with coronavirus (COVID-19) in Taiwan, and current guidelines on COVID?19 infection prevention and control. The objective of this report is to provide cytopathology professionals a timely, in?depth, evidence-based review of biosafety practices for those at risk for coronavirus (COVID-19) infection.
Laboratory biosafety, including administrative strategies and containment principles, practices, and procedures, is an important aspect of this. Following guidelines recommended by the WHO, US CDC, and the European Center for Disease Prevention and Control, as described above, our cytology laboratories in Taiwan, along with other laboratories around the world, are using a strategy that is crucial for the prevention of COVID-19 infection by our health care professionals and their families.
While confronting the global spread of COVID-19, the effectiveness of the health system is critical for building public trust and ultimately eliminating infection.Dr. Chien-Chin Chen, MD. MSc. FIAC
Cancer Cytopathol 2020 05 7;128(5):309-316. Epub 2020 Apr 7.
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
Download full-text PDF